<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433873</url>
  </required_header>
  <id_info>
    <org_study_id>115796</org_study_id>
    <nct_id>NCT02433873</nct_id>
  </id_info>
  <brief_title>Prebiotic Effects of Isomalto-oligosaccharide</brief_title>
  <official_title>Prebiotic Effects of Isomalto-oligosaccharide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Mason University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Mason University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of an IMO nutritional supplement&#xD;
      on gut microbiome, gut health, and body weight. Two formulations of the supplement will be&#xD;
      evaluated; thus, there will be three study arms: Supplement A, Supplement B, and placebo.&#xD;
      Stool samples will be analyzed for bacterial DNA. The gut bacterial DNA, body weight, and gut&#xD;
      health data will be compared across supplement and placebo groups.&#xD;
&#xD;
      Primary Aim 1: To evaluate the effect of the IMO supplement on gut bacterial abundance,&#xD;
      diversity, and gene function across intervention and placebo groups, and across two doses of&#xD;
      the intervention.&#xD;
&#xD;
      Secondary Aim 1: To evaluate the effect of the IMO supplement on gut health across&#xD;
      intervention and placebo groups, and across two doses of the intervention.&#xD;
&#xD;
      Secondary Aim 2: To evaluate the effect of the IMO supplement on body weight across&#xD;
      intervention and placebo groups, and across two doses of the intervention.&#xD;
&#xD;
      60 subjects, randomized to three arms (20 each: Supplement formula A, Supplement formula B or&#xD;
      placebo) will take a daily dose of Supplement A, Supplement B, or placebo for 8 weeks. The&#xD;
      supplement is a light syrup liquid. Ingredients that are in the supplement are:&#xD;
      isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Ingredients that&#xD;
      are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Dose&#xD;
      will be 500 mg during the first 4 weeks and then 1000 mg for second 4 weeks. Subjects will be&#xD;
      instructed to take 500 mg/day of the supplement or placebo the first four weeks and 1000&#xD;
      mg/day of the supplement or placebo for the second four weeks. Subjects will be blinded as to&#xD;
      whether they are receiving placebo or supplement. After screening and once enrolled, subject&#xD;
      involvement includes visits to George Mason University, being weighed, dropping off stool&#xD;
      samples, and completing a survey on gut health. Stool samples will be analyzed for bacterial&#xD;
      DNA. The gut bacterial DNA, weight, and gut health data will be compared across supplement&#xD;
      and placebo groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gut bacterial DNA from baseline, extracted from fecal sample</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gut bacterial DNA from baseline, extracted from fecal sample</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight change from baseline</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in self-reported digestive health measured by questionnaire</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in self-reported digestive health measured by questionnaire</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight change from baseline</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Microbiota</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isomalto-oligosaccharide</intervention_name>
    <description>Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Supplement A</arm_group_label>
    <arm_group_label>Supplement B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed and dated informed consent form&#xD;
&#xD;
          -  Willing to comply with all study procedures and be available for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Male or female, aged 18 to 45 years of age&#xD;
&#xD;
          -  In good general health as evidenced by medical history&#xD;
&#xD;
          -  Women of reproductive potential must use highly effective contraception&#xD;
&#xD;
          -  Body mass index of 25 kg/m2 or higher&#xD;
&#xD;
          -  Weigh less than 350 lbs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of colon cancer&#xD;
&#xD;
          -  History of rheumatoid arthritis&#xD;
&#xD;
          -  Active self-reported febrile illness (may enroll after 2-week waiting period following&#xD;
             the day that the illness/fever is resolved)&#xD;
&#xD;
          -  Taking TNF-alpha inhibitors, COX2 inhibitors, JAK inhibitors&#xD;
&#xD;
          -  History of hypothyroidism (with or without treatment)&#xD;
&#xD;
          -  History of inflammatory bowel disease (ulcerative colitis and Crohn's disease)&#xD;
&#xD;
          -  Type I or Type II diabetes&#xD;
&#xD;
          -  History of Parkinson's Disease, Huntington's Disease or Multiple Sclerosis&#xD;
&#xD;
          -  History of major depression, bipolar disorder, or schizophrenia&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Currently suffering from migraine headaches (at least one migraine headache in the&#xD;
             past 30 days)&#xD;
&#xD;
          -  Current use of any prescription or non-prescription weight loss products&#xD;
&#xD;
          -  Consumption of more than 2 drinks per day of alcohol&#xD;
&#xD;
          -  Tobacco smoker (over ½ pack per week is excluded)&#xD;
&#xD;
          -  Marijuana smoker (over once per month is excluded)&#xD;
&#xD;
          -  Currently have an eating disorder including anorexia nervosa, bulimia, and/or&#xD;
             obsessive compulsive disorders&#xD;
&#xD;
          -  Plan to start a new diet or make changes to their current diet during the study&#xD;
&#xD;
          -  Diagnosis of Coronary Artery Disease who have had chest pain within the past 2 months&#xD;
&#xD;
          -  Diagnosis of Congestive Heart Failure who have had any episodes of shortness of breath&#xD;
             within the last 2 months&#xD;
&#xD;
          -  History of stroke within the past 1 year&#xD;
&#xD;
          -  History of ventricular tachycardia or fibrillation&#xD;
&#xD;
          -  History of hypertension that has been difficult to control with medication (based on&#xD;
             medical history - e.g. requiring more than 2 medication to achieve control)&#xD;
&#xD;
          -  History of seizures in the last 5 years&#xD;
&#xD;
          -  Cancer diagnosis in the last 5 years (except non-melanoma skin cancer or in-situ&#xD;
             cervical cancer)&#xD;
&#xD;
          -  History of bariatric or lapband surgery&#xD;
&#xD;
          -  Usual or planned consumption of more than 2 servings per week of yogurt, kombucha,&#xD;
             kefir, or kimichi&#xD;
&#xD;
          -  Regular use of antibiotics&#xD;
&#xD;
          -  Use of antibiotics in the previous 2 weeks&#xD;
&#xD;
          -  Current and continued use of prebiotics or probiotics&#xD;
&#xD;
          -  Known allergic reactions to components of the study supplement or placebo&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cara L Frankenfeld, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Mason University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Mason University</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thitaram SN, Chung CH, Day DF, Hinton A Jr, Bailey JS, Siragusa GR. Isomaltooligosaccharide increases cecal Bifidobacterium population in young broiler chickens. Poult Sci. 2005 Jul;84(7):998-1003.</citation>
    <PMID>16050115</PMID>
  </reference>
  <reference>
    <citation>Chung CH, Day DF. Efficacy of Leuconostoc mesenteroides (ATCC 13146) isomaltooligosaccharides as a poultry prebiotic. Poult Sci. 2004 Aug;83(8):1302-6.</citation>
    <PMID>15339004</PMID>
  </reference>
  <reference>
    <citation>Chen HL, Lu YH, Lin JJ, Ko LY. Effects of isomalto-oligosaccharides on bowel functions and indicators of nutritional status in constipated elderly men. J Am Coll Nutr. 2001 Feb;20(1):44-9.</citation>
    <PMID>11294172</PMID>
  </reference>
  <reference>
    <citation>Wang HF, Lim PS, Kao MD, Chan EC, Lin LC, Wang NP. Use of isomalto-oligosaccharide in the treatment of lipid profiles and constipation in hemodialysis patients. J Ren Nutr. 2001 Apr;11(2):73-9.</citation>
    <PMID>11295027</PMID>
  </reference>
  <reference>
    <citation>Yen CH, Tseng YH, Kuo YW, Lee MC, Chen HL. Long-term supplementation of isomalto-oligosaccharides improved colonic microflora profile, bowel function, and blood cholesterol levels in constipated elderly people--a placebo-controlled, diet-controlled trial. Nutrition. 2011 Apr;27(4):445-50. doi: 10.1016/j.nut.2010.05.012. Epub 2010 Jul 10.</citation>
    <PMID>20624673</PMID>
  </reference>
  <reference>
    <citation>Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14.</citation>
    <PMID>21059476</PMID>
  </reference>
  <reference>
    <citation>Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007 Mar;5(3):352-60.</citation>
    <PMID>17368235</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>April 25, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Mason University</investigator_affiliation>
    <investigator_full_name>Cara Frankenfeld</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Microbiota</keyword>
  <keyword>Body weight</keyword>
  <keyword>Digestive system</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

